DWTX
Dogwood Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.64
−4.65%Sep 14, 2026, 12:45 UTC
Dogwood Therapeutics completed patient enrollment in its ongoing Phase 2b trial of Halneuron for chemotherapy-induced neuropathic pain, enrolling 239 patients.
Source:Aug 13, 2026, 12:30 UTC
Dogwood Therapeutics announced its financial results for the second quarter of 2026.
Source:Jul 20, 2026, 12:30 UTC
Dogwood Therapeutics enrolled the first 200 patients in its ongoing HAL-CINP Phase 2b trial for Halneuron to treat chemotherapy-induced neuropathy.
Source: